a common sexually transmitted infection (STI)
Sexually Transmitted Disease (STD) panel
Clinical Pathology Laboratories (CPL) offers a comprehensive Sexually Transmitted Disease (STD) panel, designed to detect various infections commonly transmitted through sexual contact. This panel typically includes tests for several key STDs such as Human Immunodeficiency Virus (HIV), Hepatitis B and C, Syphilis, Chlamydia, and Gonorrhea. The tests used in the panel employ a combination of methodologies, including nucleic acid amplification tests (NAATs), enzyme immunoassays (EIAs), and rapid plasma reagin (RPR) tests, among others, to accurately identify the presence of these infections.
HIV testing usually involves antibody/antigen tests to detect the virus itself or the body's response to it. Hepatitis B and C tests look for markers of these viruses in the blood, including antigens and antibodies, to indicate current or past infections. Syphilis is generally tested through serological assays to detect antibodies produced in response to the Treponema pallidum bacterium. Chlamydia and Gonorrhea, both caused by bacteria, are often detected using NAATs from urine samples or swabs from the genital area, throat, or rectum.
The STD panel is crucial for early detection and treatment of these infections, which can sometimes be asymptomatic. Early detection not only helps in initiating timely treatment for the infected individual but also plays a vital role in preventing the spread of these diseases to others. Regular testing is recommended for sexually active individuals, particularly those with multiple partners or those who engage in unprotected sex. CPL's STD panel is an essential tool in public health for managing and controlling sexually transmitted infections. It reflects the laboratory's commitment to providing accurate, sensitive, and specific diagnostic services to assist in the effective treatment and management of STDs.
Biomarkers in this category
7 biomarkers · optimal ranges shown
a sexually transmitted infection (STI)
The marker "Herpes Simplex 1 Ab, IgG" on a sexually transmitted disease (STD) test panel refers to the detection of Immunoglobulin G (IgG) antibodies specific to Herpes Simplex Virus Type 1 (HSV-1) in an individual's blood. HSV-1 is primarily known for causing oral herpes, which manifests as cold sores or fever blisters, but it can also cause genital herpes. The presence of IgG antibodies is indicative of a past or current HSV-1 infection, as these antibodies are produced by the immune system in response to the virus and remain in the body for life, providing long-term immunity. The IgG antibodies for HSV-1 typically develop within a few weeks to months after initial exposure to the virus and are detectable through serological testing. These antibodies play a critical role in controlling and containing herpes outbreaks but do not eradicate the virus. The virus resides latently in the nerve cells and can reactivate, leading to recurrent infections. Unlike IgM antibodies, which are produced first and indicate recent infection, IgG antibodies suggest a longer-term or past infection. Testing for HSV-1 IgG antibodies is important in an STD panel as it helps diagnose herpes infections, which are often asymptomatic. Many individuals infected with HSV-1 are unaware of their infection due to mild or no symptoms. By identifying the presence of antibodies, healthcare providers can advise on managing the condition and preventing transmission, particularly in sexually active individuals. HSV-1 can be transmitted through oral-to-oral contact or oral-to-genital contact, even when no symptoms are present. Thus, understanding one's HSV-1 status is crucial for informed sexual health decisions. However, the interpretation of a positive IgG test for HSV-1 can be complex, as it does not pinpoint the time of infection and cannot distinguish between oral and genital infection sites. Moreover, a positive result does not predict the frequency of future outbreaks or the severity of the symptoms. Thus, this test is typically used in conjunction with patient history and clinical symptoms to manage the infection effectively.
Blood test detecting HSV-2 antibodies; reactive means prior exposure detected.
Human Immunodeficiency Virus (HIV) is categorized into two distinct types: HIV-1 and HIV-2. Both are retroviruses that attack the body's immune system, but they have differences in their geographical prevalence, transmission rates, and progression to Acquired Immunodeficiency Syndrome (AIDS). HIV-1: This is the most common type of HIV and is found worldwide. It's responsible for the vast majority of HIV infections globally. HIV-1 is characterized by its rapid transmission and progression. It is more aggressive and infects cells faster than HIV-2, leading to a quicker decline in immune function if left untreated. HIV-1 is divided into four groups: M (Main), O (Outlier), N (Non-M, Non-O), and P, with Group M responsible for the majority of infections worldwide. Further, Group M is divided into multiple subtypes and circulating recombinant forms (CRFs). HIV-2: This type is less common and is predominantly found in West Africa, with some cases in India and Europe. Compared to HIV-1, HIV-2 is transmitted less efficiently, particularly from mother to child and through heterosexual contact. The progression of HIV-2 to AIDS is generally slower, and it may have a longer asymptomatic stage. HIV-2 is also less responsive to certain antiretroviral therapies, requiring specific treatment regimens. In terms of diagnosis, the 4th generation HIV tests are capable of detecting both HIV-1 and HIV-2. These tests look for both antibodies (the body’s immune response to the virus) and antigens (specific parts of the virus; in the case of HIV, the p24 antigen is commonly targeted). The ability to detect antigens allows these tests to identify HIV infections earlier than antibody-only tests. The management of HIV involves antiretroviral therapy (ART), which is effective for both types, although the specific treatment regimen may vary depending on whether it's HIV-1 or HIV-2. ART works by reducing the viral load in the body to undetectable levels, improving the quality of life and life expectancy of infected individuals, and significantly reducing the risk of transmission. Understanding the differences between HIV-1 and HIV-2 is crucial for effective treatment and epidemiological control. Both types of HIV can lead to the weakening of the immune system, making individuals more susceptible to other infections and diseases. Early detection and appropriate treatment are key to managing the infection and preventing its spread. The management of HIV involves antiretroviral therapy (ART), which is effective for both types, although the specific treatment regimen may vary depending on whether it's HIV-1 or HIV-2. ART works by reducing the viral load in the body to undetectable levels, improving the quality of life and life expectancy of infected individuals, and significantly reducing the risk of transmission. Understanding the differences between HIV-1 and HIV-2 is crucial for effective treatment and epidemiological control. Both types of HIV can lead to the weakening of the immune system, making individuals more susceptible to other infections and diseases. Early detection and appropriate treatment are key to managing the infection and preventing its spread. The marker "HIV 1/2 4th Gen, RFLX Conf" on a sexually transmitted disease (STD) test panel refers to the fourth-generation testing for Human Immunodeficiency Virus (HIV) Types 1 and 2, with reflex to confirmatory testing. This advanced testing methodology significantly enhances the early detection of HIV, the virus responsible for Acquired Immunodeficiency Syndrome (AIDS). Fourth-generation tests are designed to detect both HIV antigens (specifically, the p24 antigen which appears soon after infection and before antibodies are made) and antibodies (the immune response to the virus). This dual detection approach allows for the identification of acute HIV infections earlier than previous generation tests that only detected antibodies. The "RFLX Conf" part of the marker indicates that if the initial test is reactive, indicating the possible presence of HIV, the sample will automatically undergo additional confirmatory testing. This typically involves an HIV-1/HIV-2 antibody differentiation immunoassay to confirm the presence of HIV and determine whether it is type 1 or type 2. In some cases, if the differentiation assay is inconclusive, a nucleic acid test (NAT) may be performed to detect the virus's genetic material directly. The inclusion of this test in STD panels is critical due to the asymptomatic nature of early HIV infection and the significant public health implications of undiagnosed HIV. Early detection through the fourth-generation test allows for timely initiation of antiretroviral therapy (ART), which is crucial for managing HIV, reducing the risk of transmission, and improving long-term health outcomes. Additionally, early intervention has been shown to significantly reduce the risk of HIV-related complications and transmission to others, underscoring the importance of including this test in comprehensive STD testing and early intervention strategies. NOTE: The performance of this assay has not been established for individuals younger than 2 years of age. Nearly all infants born to HIV-infected mothers passively acquire maternal antibody and may test antibody positive until 18 months regardless of infection status. Definitive diagnosis requires other assays, including HIV nucleic acid tests.
a critical diagnostic tool for syphilis
aid in assessment and management of syphilis